1 Min Read
Nov 15 (Reuters) - Promius Pharma LLC
* announces ZEMBRACE® SymTouch® (sumatriptan injection) 3 mg achieves primary endpoint in post-approval clinical trial Source text for Eikon:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.